Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.

Trial Details

NCT ID
NCT07321912
Phase
PHASE2
Sponsor
Milton S. Hershey Medical Center
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Eflornithine
  • Topotecan
  • Cyclophosphamide
  • Vincristine
  • Doxorubicin
  • Ifosfamide
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843
  • Hershey, Pennsylvania, United States|40.28592,-76.65025

Key Eligibility Criteria

  • Participants must be ≤50 years of age at enrollment.
  • Histologically confirmed Ewing sarcoma that is refractory or in first or subsequent relapse. Histological confirmation either at initial diagnosis …
  • Relapsed: Participants that have achieved CR at any point and then relapsed following/during standard of care therapy.
  • Refractory: Participants that failed to achieve CR after standard of care therapy or having progressed during standard of care therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →